EBV Seropositivity in Liver Donors
Approximately 94% of deceased liver donors are EBV seropositive, meaning only about 6% of potential liver donors are EBV seronegative 1.
Key Epidemiologic Data
The most relevant study examining organ donor EBV serostatus analyzed 459 deceased organ donors and found:
- 94% were EBV IgG antibody positive
- Only 27 donors (6%) were EBV seronegative 1
This creates a significant challenge for EBV-seronegative recipients, particularly pediatric patients, as the donor-positive/recipient-negative (D+/R-) mismatch carries the highest risk for post-transplant lymphoproliferative disorder (PTLD) 2.
Age-Related Patterns
EBV seropositivity increases rapidly with age:
- By ages 17-29 years: 90% of organ donors are EBV seropositive 3
- Younger donors (≤35 years) have higher rates of EBV seronegativity (74% of EBV-negative donors fall in this age group) 1
- This age distribution actually benefits pediatric recipients who need age-matched organs and are more likely to be EBV-negative themselves 1
Geographic and Demographic Variations
Canadian data shows some regional variation, though this is more pronounced for CMV than EBV 3. Women are more likely to be EBV seropositive than men (OR = 1.87 for organ donors) 3.
Clinical Implications
The scarcity of EBV-seronegative donors (only 6%) means that most EBV-negative recipients will receive organs from EBV-positive donors, necessitating careful post-transplant monitoring. Current guidelines emphasize that EBV-mismatched transplants (D+/R-) require surveillance for EBV DNAemia as part of PTLD prevention strategies 4, with monitoring focused particularly on months 2-6 post-transplant when donor-acquired EBV DNAemia is most common 5.
The high baseline EBV seropositivity rate in the donor pool (94%) underscores why prospective EBV testing of donors and appropriate allocation strategies are critical for optimizing outcomes, particularly in pediatric transplantation 1.